Nuvilex (PMCB) Competitors $1.01 +0.02 (+1.55%) Closing price 08/5/2025 03:58 PM EasternExtended Trading$1.30 +0.29 (+28.08%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. ADAP, CLNN, RNTX, SCYX, PMN, NNVC, TPST, CING, FBLG, and QTTBShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include Adaptimmune Therapeutics (ADAP), Clene (CLNN), Rein Therapeutics (RNTX), SCYNEXIS (SCYX), Promis Neurosciences (PMN), NanoViricides (NNVC), Tempest Therapeutics (TPST), Cingulate (CING), FibroBiologics (FBLG), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors Adaptimmune Therapeutics Clene Rein Therapeutics SCYNEXIS Promis Neurosciences NanoViricides Tempest Therapeutics Cingulate FibroBiologics Q32 Bio Nuvilex (NASDAQ:PMCB) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Which has higher valuation & earnings, PMCB or ADAP? Nuvilex has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvilexN/AN/A$330K$0.741.37Adaptimmune Therapeutics$178.03M0.14-$70.81M-$0.27-0.35 Which has more volatility and risk, PMCB or ADAP? Nuvilex has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Do analysts recommend PMCB or ADAP? Adaptimmune Therapeutics has a consensus target price of $1.35, indicating a potential upside of 1,321.31%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Nuvilex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is PMCB or ADAP more profitable? Nuvilex has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -38.91%. Nuvilex's return on equity of 0.51% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvilexN/A 0.51% 0.35% Adaptimmune Therapeutics -38.91%-163.73%-23.65% Do institutionals & insiders hold more shares of PMCB or ADAP? 34.2% of Nuvilex shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 10.2% of Nuvilex shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer PMCB or ADAP? In the previous week, Adaptimmune Therapeutics had 12 more articles in the media than Nuvilex. MarketBeat recorded 12 mentions for Adaptimmune Therapeutics and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 beat Adaptimmune Therapeutics' score of -0.71 indicating that Nuvilex is being referred to more favorably in the media. Company Overall Sentiment Nuvilex Neutral Adaptimmune Therapeutics Negative SummaryNuvilex beats Adaptimmune Therapeutics on 8 of the 15 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.86M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.71%4.14%P/E Ratio1.379.1628.8923.88Price / SalesN/A717.24447.6498.82Price / CashN/A159.4135.6858.35Price / Book0.315.078.165.60Net Income$330K$31.61M$3.25B$265.26M7 Day Performance0.50%-0.38%1.12%-0.15%1 Month Performance-7.81%5.79%8.22%6.07%1 Year Performance-47.95%3.58%29.12%24.21% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex1.5075 of 5 stars$1.02+1.6%N/A-47.1%$6.86MN/A1.374Positive NewsUpcoming EarningsADAPAdaptimmune Therapeutics2.6628 of 5 stars$0.10+4.9%$1.35+1,188.5%-90.3%$27.80M$178.03M-0.39490Upcoming EarningsGap UpHigh Trading VolumeCLNNClene3.055 of 5 stars$3.36-1.2%$40.00+1,090.5%-7.8%$27.78M$350K-0.83100News CoverageRNTXRein TherapeuticsN/A$1.25-11.3%N/AN/A$27.69MN/A-0.449Positive NewsGap DownSCYXSCYNEXIS0.4454 of 5 stars$0.71-3.2%N/A-63.2%$27.67M$3.75M-1.2760PMNPromis Neurosciences2.0505 of 5 stars$0.84-6.7%$4.33+415.8%-44.2%$27.46MN/A-16.805NNVCNanoViricides0.5089 of 5 stars$1.70flatN/A-21.8%$27.32MN/A-2.3620TPSTTempest Therapeutics2.2809 of 5 stars$7.26-10.1%$30.00+313.2%-59.1%$26.72MN/A-0.4020CINGCingulate3.4055 of 5 stars$5.16-1.1%$26.00+403.9%+1,737.3%$26.57MN/A-0.6120Upcoming EarningsGap DownFBLGFibroBiologics3.2315 of 5 stars$0.61-7.5%$13.00+2,042.0%-85.3%$26.03MN/A-2.8910Earnings ReportAnalyst ForecastHigh Trading VolumeQTTBQ32 Bio1.7256 of 5 stars$2.12-4.9%$12.17+473.9%-94.8%$25.86MN/A-0.4339Negative NewsShort Interest ↑Gap Down Related Companies and Tools Related Companies ADAP Competitors CLNN Competitors RNTX Competitors SCYX Competitors PMN Competitors NNVC Competitors TPST Competitors CING Competitors FBLG Competitors QTTB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
